B7S1, a novel candidate for anti-tumor checkpoint blockade immunotherapy

Sci China Life Sci. 2018 Sep;61(9):1132-1134. doi: 10.1007/s11427-018-9321-0. Epub 2018 Jun 21.

Authors

Xiangyu Chen¹, Lilin Ye²

Affiliations

¹ Institute of Immunology, Third Military Medical University, Chongqing, 400038, China.
² Institute of Immunology, Third Military Medical University, Chongqing, 400038, China. yelilinlcmv@tmmu.edu.cn.

PMID: 30069671
DOI: 10.1007/s11427-018-9321-0

No abstract available

MeSH terms

CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / metabolism
Humans
Immunotherapy / methods*
Ligands
Models, Immunological
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / therapy*
Programmed Cell Death 1 Receptor / immunology
Programmed Cell Death 1 Receptor / metabolism
V-Set Domain-Containing T-Cell Activation Inhibitor 1 / immunology*
V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism

Substances

Ligands
Programmed Cell Death 1 Receptor
V-Set Domain-Containing T-Cell Activation Inhibitor 1
VTCN1 protein, human